Differences in the receptor status between primary and recurrent breast cancer - The frequency of and the reasons for discordance

Oncology (Switzerland)

Volumn 84, Issue 6, 2013, Pages 319-325

  Heitz, Florian ^a,b   Barinoff, Jana ^a,b   Du Bois, Ondra ^b   Hils, Rita ^b   Fisseler Eckhoff, Annette ^b   Harter, Philipp ^a,b   Heitz, Julia ^c   Willenbrock, Klaus ^b   Traut, Alexander ^a,b   Du Bois, Andreas ^a,b  

^a KLINIKEN ESSEN MITTE   (Germany)

^b DR HORST SCHMIDT KLINIKEN   (Germany)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Breast cancer biopsy; Breast cancer phenotypes; Metastatic breast cancer; Receptor change; Receptor discordance; Recurrent breast cancer

Indexed keywords

AROMATASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GONADORELIN ANTAGONIST; PROGESTERONE RECEPTOR; TAMOXIFEN; TRASTUZUMAB; ESTROGEN; HORMONE RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; CANCER PATIENT; COMPARATIVE STUDY; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; PHENOTYPE; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENT CANCER; CANCER THERAPY; DISEASE ASSOCIATION; FEMALE; MIDDLE AGED; PROSPECTIVE STUDY; RECURRENT DISEASE; TERTIARY CARE CENTER; TUMOR RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CONFIDENCE INTERVALS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; ODDS RATIO; PROSPECTIVE STUDIES; RECEPTOR, ERBB-2; RECEPTORS, ESTRADIOL; RECEPTORS, PROGESTERONE; TIME FACTORS;

EID: 84876455995     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000346184     Document Type: Article

References (54)

1. GLOBOCAN 2008 [database on the Internet].
2. Geneva, World Health Organisation, 2012, http://globocan.iarc.fr/ factsheet.asp.
3. Kataja V, Castiglione M: Primary breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009; 20(suppl 4):10-14.
4. Hammond ME: ASCO-CAP guidelines for breast predictive factor testing: An update. Appl Immunohistochem Mol Morphol 2011; 19: 499-500.
5. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007; 25: 118-145.
6. Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005; 365: 1687-1717.
7. Barinoff J, Hils R, Bender A, Gross J, Kurz C, Tauchert S, et al: Clinicopathological differences between breast cancer in patients with primary metastatic disease and those without: A multicentre study. Eur J Cancer 2013; 49: 305-311.
8. Lindström LS, Karlsson E, Wilking UM, Johansson U, Hartman J, Lidbrink EK, et al: Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. J Clin Oncol 2012; 30: 2601-2608.
9. Bogina G, Bortesi L, Marconi M, Venturini M, Lunardi G, Coati F, et al: Comparison of hormonal receptor and HER-2 status between breast primary tumours and relapsing tumours: Clinical implications of progesterone receptor loss. Virchows Arch 2011; 459: 1-10.
10. Johnston SR, Saccani-Jotti G, Smith IE, Salter J, Newby J, Coppen M, et al: Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer. Cancer Res 1995; 55: 3331-3338.
11. Tanner M, Jarvinen P, Isola J: Amplification of HER-2/neu and topoisomerase IIα in primary and metastatic breast cancer. Cancer Res 2001; 61: 5345-5348.
12. Lower EE, Glass E, Blau R, Harman S: HER-2/neu expression in primary and metastatic breast cancer. Breast Cancer Res Treat 2009; 113: 301-306.
13. Simmons C, Miller N, Geddie W, Gianfelice D, Oldfield M, Dranitsaris G, et al: Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases? Ann Oncol 2009; 20: 1499-1504.
14. Amir E, Miller N, Geddie W, Freedman O, Kassam F, Simmons C, et al: Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer. J Clin Oncol 2012; 30: 587-592.
15. Liedtke C, Broglio K, Moulder S, Hsu L, Kau SW, Symmans WF, et al: Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. Ann Oncol 2009; 20: 1953-1958.
16. Tavassoli F, Devilee P (eds): Tumours of the Breast. Lyon, IARC, 2003.
17. Coradini D, Oriana S, Ditto A, Bresciani G, Difronzo G: Receptor status variation in primary breast cancer and subsequent accessible relapse. Int J Oncol 1996; 8: 997-1002.
18. Spataro V, Price K, Goldhirsch A, Cavalli F, Simoncini E, Castiglione M, et al: Sequential estrogen receptor determinations from primary breast cancer and at relapse: Prognostic and therapeutic relevance. The International Breast Cancer Study Group (formerly Ludwig Group). Ann Oncol 1992; 3: 733-740.
19. Guarneri V, Giovannelli S, Ficarra G, Bettelli S, Maiorana A, Piacentini F, et al: Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: Impact on patient management. Oncologist 2008; 13: 838-844.
20. Gomez-Fernandez C, Daneshbod Y, Nassiri M, Milikowski C, Alvarez C, Nadji M: Immunohistochemically determined estrogen receptor phenotype remains stable in recurrent and metastatic breast cancer. Am J Clin Pathol 2008; 130: 879-882.
21. Wu JM, Fackler MJ, Halushka MK, Molavi DW, Taylor ME, Teo WW, et al: Heterogeneity of breast cancer metastases: Comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases. Clin Cancer Res 2008; 14: 1938-1946.
22. Amir E, Ooi WS, Simmons C, Kahn H, Christakis M, Popovic S, et al: Discordance between receptor status in primary and metastatic breast cancer: An exploratory study of bone and bone marrow biopsies. Clin Oncol (R Coll Radiol) 2008; 20: 763-768.
23. Santinelli A, Pisa E, Stramazzotti D, Fabris G: HER-2 status discrepancy between primary breast cancer and metastatic sites. Impact on target therapy. Int J Cancer 2008; 122: 999-1004.
24. Broom RJ, Tang PA, Simmons C, Bordeleau L, Mulligan AM, O'Malley FP, et al: Changes in estrogen receptor, progesterone receptor and Her-2/neu status with time: Discordance rates between primary and metastatic breast cancer. Anticancer Res 2009; 29: 1557-1562.
25. Hoefnagel LD, van de Vijver MJ, van Slooten HJ, Wesseling P, Wesseling J, Westenend PJ, et al: Receptor conversion in distant breast cancer metastases. Breast Cancer Res 2010; 12:R75.
26. Idirisinghe PK, Thike AA, Cheok PY, Tse GM, Lui PC, Fook-Chong S, et al: Hormone receptor and c-ERBB2 status in distant metastatic and locally recurrent breast cancer. Pathologic correlations and clinical significance. Am J Clin Pathol 2010; 133: 416-429.
27. Sari E, Guler G, Hayran M, Gullu I, Altundag K, Ozisik Y: Comparative study of the immunohistochemical detection of hormone receptor status and HER-2 expression in primary and paired recurrent/metastatic lesions of patients with breast cancer. Med Oncol 2011; 28: 57-63.
28. Xiao C, Gong Y, Han EY, Gonzalez-Angulo AM, Sneige N: Stability of HER2-positive status in breast carcinoma: A comparison between primary and paired metastatic tumors with regard to the possible impact of intervening trastuzumab treatment. Ann Oncol 2011; 22: 1547-1553.
29. Curigliano G, Bagnardi V, Viale G, Fumagalli L, Rotmensz N, Aurilio G, et al: Should liver metastases of breast cancer be biopsied to improve treatment choice? Ann Oncol 2011; 22: 2227-2233.
30. Holdaway IM, Bowditch JV: Variation in receptor status between primary and metastatic breast cancer. Cancer 1983; 52: 479-485.
31. Nomura Y, Tashiro H, Shinozuka K: Changes of steroid hormone receptor content by chemotherapy and/or endocrine therapy in advanced breast cancer. Cancer 1985; 55: 546-551.
32. Crawford DJ, Cowan S, Fitch R, Smith DC, Leake RE: Stability of oestrogen receptor status in sequential biopsies from patients with breast cancer. Br J Cancer 1987; 56: 137-140.
33. Kuukasjarvi T, Kononen J, Helin H, Holli K, Isola J: Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy. J Clin Oncol 1996; 14: 2584-2589.
34. Mobbs BG: Effect of time and therapy on the hormone receptor status of breast carcinomas. Can Med Assoc J 1982; 127: 217-221.
35. Mobbs BG, Johnson IE: Use of an enzymeimmunoassay (EIA) for quantitation of cytosolic and nuclear estrogen receptor, and correlation with progesterone receptor in human breast cancer. J Steroid Biochem 1987; 28: 653-662.
36. Sekido Y, Umemura S, Takekoshi S, Suzuki Y, Tokuda Y, Tajima T, et al: Heterogeneous gene alterations in primary breast cancer contribute to discordance between primary and asynchronous metastatic/recurrent sites: HER2 gene amplification and p53 mutation. Int J Oncol 2003; 22: 1225-1232.
37. Niehans GA, Singleton TP, Dykoski D, Kiang DT: Stability of HER-2/neu expression over time and at multiple metastatic sites. J Natl Cancer Inst 1993; 85: 1230-1235.
38. Gancberg D, Di Leo A, Cardoso F, Rouas G, Pedrocchi M, Paesmans M, et al: Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. Ann Oncol 2002; 13: 1036-1043.
39. Vincent-Salomon A, Jouve M, Genin P, Freneaux P, Sigal-Zafrani B, Caly M, et al: HER2 status in patients with breast carcinoma is not modified selectively by preoperative chemotherapy and is stable during the metastatic process. Cancer 2002; 94: 2169-2173.
40. Bozzetti C, Personeni N, Nizzoli R, Guazzi A, Flora M, Bassano C, et al: HER-2/neu amplification by fluorescence in situ hybridization in cytologic samples from distant metastatic sites of breast carcinoma. Cancer 2003; 99: 310-315.
41. Zidan J, Dashkovsky I, Stayerman C, Basher W, Cozacov C, Hadary A: Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease. Br J Cancer 2005; 93: 552-556.
42. Gong Y, Booser DJ, Sneige N: Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma. Cancer 2005; 103: 1763-1769.
43. Gutierrez MC, Detre S, Johnston S, Mohsin SK, Shou J, Allred DC, et al: Molecular changes in tamoxifen-resistant breast cancer: Relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. J Clin Oncol 2005; 23: 2469-2476.
44. Tapia C, Savic S, Wagner U, Schonegg R, Novotny H, Grilli B, et al: HER2 gene status in primary breast cancers and matched distant metastases. Breast Cancer Res 2007; 9:R31.
45. Allegra JC, Barlock A, Huff KK, Lippman ME: Changes in multiple or sequential estrogen receptor determinations in breast cancer. Cancer 1980; 45: 792-794.
46. Chambers AF, Groom AC, MacDonald IC: Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2002; 2: 563-572.
47. Hawkins RA, Tesdale AL, Anderson ED, Levack PA, Chetty U, Forrest AP: Does the oestrogen receptor concentration of a breast cancer change during systemic therapy? Br J Cancer 1990; 61: 877-880.
48. Raemaekers JM, Beex LV, Koenders AJ, Pieters GF, Smals AG, Benraad TJ, et al: Concordance and discordance of estrogen and progesterone receptor content in sequential biopsies of patients with advanced breast cancer: Relation to survival. Eur J Cancer Clin Oncol 1984; 20: 1011-1018.
49. Webster DJ, Bronn DG, Minton JP: Estrogen receptor levels in multiple biopsies from patients with breast cancer. Am J Surg 1978; 136: 337-338.
50. Rosen PP, Menendez-Botet CJ, Urban JA, Fracchia A, Schwartz MK: Estrogen receptor protein (ERP) in multiple tumor specimens from individual patients with breast cancer. Cancer 1977; 39: 2194-2200.
51. Mittendorf EA, Wu Y, Scaltriti M, Meric-Bernstam F, Hunt KK, Dawood S, et al: Loss of HER2 amplification following trastuzumabbased neoadjuvant systemic therapy and survival outcomes. Clin Cancer Res 2009; 15: 7381-7388.
52. Hurley J, Doliny P, Reis I, Silva O, Gomez-Fernandez C, Velez P, et al: Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer. J Clin Oncol 2006; 24: 1831-1838.
53. Burstein HJ, Harris LN, Gelman R, Lester SC, Nunes RA, Kaelin CM, et al: Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: A pilot study. J Clin Oncol 2003; 21: 46-53.
54. Wu JM, Halushka MK, Argani P: Intratumoral heterogeneity of HER-2 gene amplification and protein overexpression in breast cancer. Hum Pathol 2010; 41: 914-917.